17th week of 2014 patent applcation highlights part 37 |
Patent application number | Title | Published |
20140112884 | COMPOSITION AND METHOD FOR TREATING CANCER - Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same. | 2014-04-24 |
20140112885 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2014-04-24 |
20140112886 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2′-methyl nucleotides linked according to Formula I: | 2014-04-24 |
20140112887 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′,4′-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2′,4′-bridged nucleosides are of Formula 3001: | 2014-04-24 |
20140112888 | Viral Hepatitis Treatment - The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions. | 2014-04-24 |
20140112889 | METHOD FOR REDUCING METHANE PRODUCTION IN A RUMINANT ANIMAL - A method for reducing methane production in a ruminant animal comprising the step of administering to said ruminant animal an effective amount of at least one strain of bacterium of the genus | 2014-04-24 |
20140112890 | INTRAOPERATIVE AND BLOOD DERIVED ADHESIVES - The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency. | 2014-04-24 |
20140112891 | AUTOLOGOUS HUMAN ADULT PLURIPOTENT VERY SMALL EMBRYONIC-LIKE (hVSEL) STEM CELL REGENERATION OF BONE AND CARTILAGE - The invention provides methods and compositions for the repair or regeneration of osteochondral tissue. The methods and compositions provide an effective amount of isolated differentiable human Very Small Embryonic Like Stem Cells (hVSELs) sufficient for regeneration or repair of an osteochondral tissue. The compositions can be administered directly to the tissue or administered systemically. | 2014-04-24 |
20140112892 | SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE - The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them. | 2014-04-24 |
20140112893 | ENHANCED MSC PREPARATIONS - The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof. | 2014-04-24 |
20140112894 | AUTOLOGOUS CELLS ON A SUPPORT MATRIX FOR TISSUE REPAIR - The present invention relates to a method for the effective treatment of tissue defects and for tissue regeneration. The method includes seeding autologous cells on a support matrix and implanting the cell-seeded support matrix into a site of transplantation. The present invention also relates to various tissue repair structures that include cells seeded onto a cell-free membrane. The present invention also provides methods for cultivation, seeding, and implantation of autologous cells. | 2014-04-24 |
20140112895 | GLP-1 PROMOTER MEDIATED INSULIN EXPRESSION FOR THE TREATMENT OF DIABETES - Insulin gene therapy is one of many envisioned alternative treatments of diabetes. Diabetes gene therapy would be possible if insulin could be produced in a regulated and specifically in a sensitive manner dependent on the blood glucose level. Therefore, the present invention relates to a method for the isolation of GLP-1 expressing cells, to nucleic acids sequence construction or vectors useful for isolating GLP-1 expressing cell and to the GLP-1 expressing cells isolated therewith. Furthermore, the invention relates to a method of nucleic acids sequence construction or vectors under the control of the GLP-1 promoter expressing insulin in a recombinant GLP-1 expressing cell line. The cells of the present invention are particular useful for the treatment of diabetes and may be used in a gene therapy approach to treat diabetes and other disorders related to the nutrient metabolism. | 2014-04-24 |
20140112896 | METHODS AND COMPOSITIONS FOR THE PROVISION OF PROTEINS DEFICIENT IN LYSOSOMAL STORAGE DISEASES - Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for the provision of proteins lacking or deficient in subjects with a lysosomal storage disease and treatment and/or prevention of lysosomal storage diseases. | 2014-04-24 |
20140112897 | Treatment of Respiratory Tract Illness with Bifidobacterium Lactis BL-04 - The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising | 2014-04-24 |
20140112898 | UNIQUE POPULATION OF REGULATORY T CELLS THAT REGULATE TISSUE REGENERATION AND WOUND HEALING - A unique type of regulatory T cell has been identified in muscle. These tissue-regenerative Treg cells play a role in regulating wound healing. These cells, as well as agents that control their differentiation and/or activity and agents produced by the cells, can be used to modulate wound healing and the differentiation of muscle cells. | 2014-04-24 |
20140112899 | USE OF AN ENAMINOCARBONYL COMPOUND IN COMBINATION WITH A BIOLOGICAL CONTROL AGENT - A combination comprising an enaminocarbonyl compound of formula (I): wherein R is methyl, cyclopropyl or 2,2-difluoroethyl, and at least one biological control agent selected from bacteria, fungi or yeasts, protozoas, viruses, and entomopathogenic nematodes, and optionally an inoculant, for reducing overall damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, mites nematodes and phytopathogens. | 2014-04-24 |
20140112900 | Solubilized CoQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules. | 2014-04-24 |
20140112901 | STABLE COMPOSITIONS CONTAINING THROMBIN AND METHODS FOR PREPARATION AND USE THEREOF - Compositions comprising thrombin and collagen and methods of preparation thereof are disclosed herein. In one embodiment, a composition comprises thrombin and collagen in an aqueous buffer solution, wherein the buffer solution includes at least one of a first compound represented by Formula I: R | 2014-04-24 |
20140112902 | METHODS FOR TREATMENT OF INFLAMMATORY AND INFECTIOUS DISEASES - Methods and therapeutic treatments of diseases such as viral infections are provided including applying peg-Arginase I. Methods are provided that treat inflammation mediated diseases with peg-Arginase I. | 2014-04-24 |
20140112903 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2014-04-24 |
20140112904 | METHOD FOR ENHANCING THE CLEAVAGE ACTIVITY OF I-CREI DERIVED MEGANUCLEASES - A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position 79, the valine at position 105 and the isoleucine at position 132 of I-CreI, and its application for the manufacturing of meganuclease cleaving a DNA target of interest, for use in genome therapy (treatment of genetic diseases) and genome engineering (making of transgenic animals, transgenic plants and recombinant cell lines). | 2014-04-24 |
20140112905 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 2014-04-24 |
20140112906 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 2014-04-24 |
20140112907 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 2014-04-24 |
20140112908 | NON-PROTEIN STABILIZED CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS - A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol. | 2014-04-24 |
20140112909 | METHODS AND FORMULATIONS PROMOTING TISSUE/ORGAN REGENERATION, LONGEVITY AND HEALTHSPAN - A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day. | 2014-04-24 |
20140112910 | MODIFIED GLYCOPROTEINS - Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described. | 2014-04-24 |
20140112911 | NOVEL ANTI-CMET ANTIBODY - The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met. The invention finally comprises products and/or compositions comprising such an antibody in combination with other antibodies and/or chemical compounds directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2014-04-24 |
20140112912 | DIAGNOSIS AND TREATMENT OF AUTOANTIBODY-MEDIATED HEART DISEASE - Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of IgG4 antibodies to cardiac autoantigens. | 2014-04-24 |
20140112913 | METHODS OF PROGNOSING AND ADMINISTERING TREATMENT FOR INFLAMMATORY DISORDERS - The present invention provides methods for determining responsiveness to an IL-6 inhibitor JAK/STAT pathway inhibitor in a subject. The present invention also provides methods for treating disease with an IL-6 inhibitor or a JAK/STAT pathway inhibitor. | 2014-04-24 |
20140112914 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT - By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells. | 2014-04-24 |
20140112915 | IL-18 binding molecules - IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool. | 2014-04-24 |
20140112916 | Optimized Antibodies That Target CD19 - The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 2014-04-24 |
20140112917 | DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER - Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab. | 2014-04-24 |
20140112918 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); | 2014-04-24 |
20140112919 | INTERLEUKIN-10 ANTIBODIES - The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology. | 2014-04-24 |
20140112920 | METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS - Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. | 2014-04-24 |
20140112921 | Increased Bioavailability of Transdermally Delivered Agents - A method for delivering a bioactive agent to the cardiovascular system is described. The method delivers the agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body. For instance, little or none of the bioactive agent will be sequestered in lymph tissue and prevented from circulation in the cardiovascular system. The method includes utilization of a transdermal delivery device including microneedles with structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. | 2014-04-24 |
20140112922 | TARGETED PROTEIN SILENCING USING CHIMERAS BETWEEN ANTIBODIES AND UBIQUITINATION ENZYMES - The present invention relates to an isolated chimeric molecule comprising a degradation domain including a eukaryotic U-box motif and a targeting domain capable of immuno specifically directing the degradation domain to a substrate where the targeting domain is heterologous to the degradation domain. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers. | 2014-04-24 |
20140112923 | EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN - Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment. | 2014-04-24 |
20140112924 | NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes. | 2014-04-24 |
20140112925 | SINGLE CHAIN ANTIGEN RECOGNIZING CONSTRUCTS (scARCs) STABILIZED BY THE INTRODUCTION OF NOVEL DISULFIDE BONDS - The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC. The invention further encompasses pharmaceutical compositions containing the scARC of the invention and the use of the scARC in therapy of cancerous or infectious diseases, or for use in the quantification and/or visualization of disease associated antigens. | 2014-04-24 |
20140112926 | Fc VARIANTS - Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins. | 2014-04-24 |
20140112927 | BISPECIFIC MONOCLONAL ANTIBODY THERAPEUTICS AGAINST WEST NILE VIRUS WITH IMPROVED CNS PENETRATION - The plant-based production of a therapeutic antibody against West Nile Virus is disclosed. | 2014-04-24 |
20140112928 | ANTIBODIES AGAINST TROPOMYOSIN-RELATED KINASE B RECEPTORS - The invention relates to monoclonal antibodies directed to a particular part of tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines producing these. Fragments of these antibodies, in particular fragments representing complementarity determining regions (CDRs), and proteins comprising these, are useful in a method of treating cancer, pain, anorexia, anorexia nervosa and/or cachexia. | 2014-04-24 |
20140112929 | TUMOUR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS - The invention relates to TNFR1 binding proteins, in particular those which are capable of preventing dimerisation of TNFR1 chains, and to their use in therapy. | 2014-04-24 |
20140112930 | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) - The present invention provides methods for treating or preventing malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2). | 2014-04-24 |
20140112931 | ANTI-HUMAN HER3 ANTIBODIES AND USES THEREOF - The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer. | 2014-04-24 |
20140112932 | Methods for Treating GI Syndrome and Graft versus Host Disease - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 2014-04-24 |
20140112933 | Antibodies Against Angiopoietins 1 and 2, and Their Use - The present invention relates to antibodies against angiopoietins 1 and 2, and derivatives of these antibodies. More specifically, the present invention relates to therapeutic use of the antibodies and fragment thereof which specifically bind to angiopoietins 1 and 2. | 2014-04-24 |
20140112934 | COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASES - The present invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections. | 2014-04-24 |
20140112935 | ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF - The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer. | 2014-04-24 |
20140112936 | METHODS OF NEUTRALIZING VIRAL INFECTION - Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin Fd intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided. | 2014-04-24 |
20140112937 | USE OF AN AGENT CONSISTING OF ANTIBODIES AND/OR INSULIN-LIKE GROWTH FACTOR ANTAGONISTS - The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases. | 2014-04-24 |
20140112938 | COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ENTERIC BACTERIAL INFECTIONS - The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine. | 2014-04-24 |
20140112939 | Methods for Inhibiting Osteolysis - The invention provides methods and compositions for reducing or inhibiting osteolysis, bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that inhibits the biological activity of an axon guidance protein. The compound or agent my inhibit transcription or translation of or bind to an axon guidance protein, such as, for instance, a netrin like netrin-1. Likewise, the compound or agent may inhibit transcription or translation of or bind to a receptor of an axon guidance protein, such as, for instance, a netrin receptor such as unc5b. In some instances, the compound or agent is an agonist of an adenosine A | 2014-04-24 |
20140112940 | MYCOTOXIN DIAGNOSTICS AND METHODS THEREOF - The current invention is directed towards a rapid, reproducible test for the fungal virulence factors and associated affected compounds so that patients at risk for autism, cerebral palsy and other human diseases can be quickly identified, treated and possibly prevented. This includes a multitude of test protocols for both the mycotoxin gliotoxin and its relationship with glutathione- and relates the two molecules by a novel paradigm known as the Glutathione-Gliotoxin Index-(GGI) or Disease-Disorder Susceptibility Index-D/DSI, which indicates the Autism Susceptibility Index-(ASI). One testing device and protocol includes a cellular phone application with modification to test for susceptibility to autism and other disease states. Of particular relevance for autism is the role of glutathione depletion by gliotoxin, then by the anti-pyretic acetaminophen in the peri-vaccination period, which each result in oxidative stress and metal intoxication, by disrupting the metallothionein system, amongst other biochemical pathways and numerous enzyme systems. | 2014-04-24 |
20140112941 | MAMMALIAN RECEPTORS AS TARGETS FOR ANTIBODY AND ACTIVE VACCINATION THERAPY AGAINST MOLD INFECTIONS - The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide. | 2014-04-24 |
20140112942 | AGONISTIC ANTIBODY TO CD27 - The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim | 2014-04-24 |
20140112943 | METHOD OF DEVELOPING A VACCINE USING PEPTIDE-POLY IC COMPLEXES - The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified so they can spontaneously form complexes with a synthetic nucleic acid, such as Poly IC, that functions as an immunological adjuvant. The peptide-nucleic acid complexes are dramatically more immunogenic as compared to the separate components. The procedure for developing the vaccine involves the conjugation of a synthetic peptide containing a C residue to poly-K using a bi-functional cross-linking reagent (SMCC). The peptide/poly-K complex was then formulated with CMC and poly-IC to produce a self-adjuvant vaccine that was 36-fold more effective as compared to the same peptide administered mixed with the same adjuvant (but not complexed to it). | 2014-04-24 |
20140112944 | COMPOSITIONS AND METHODS FOR TREATING CANCER - This invention generally relates to compositions and methods for targeted delivery of chemotherapeutic agents to cancerous and pre-cancerous cells, thereby treating a cancer in a subject. | 2014-04-24 |
20140112945 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES - The compounds of formula (1) | 2014-04-24 |
20140112946 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2- -DIHYDROQUINOLINE-3-CARBOXAMIDE - Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease. | 2014-04-24 |
20140112947 | Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor - The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses. | 2014-04-24 |
20140112948 | Multi-Target Recombination Gene and the Application of its Protein to Prevent and Cure Helicobacter Pylori - The present invention discloses a multi-target recombination gene and the application of its protein to prevent and cure | 2014-04-24 |
20140112949 | Recombinant Mycobacterium Avium Subsp. Paratuberculosis Proteins Induce Immunity and Protect Against Infection - Compositions of immunogenic proteins of | 2014-04-24 |
20140112950 | COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT - Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant. | 2014-04-24 |
20140112951 | Vaccine and drug delivery by topical application of vectors and vector extracts - Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response. | 2014-04-24 |
20140112952 | ATTENUATED POLIOVIRUSES - The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5′ non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs. | 2014-04-24 |
20140112953 | INACTIVATED DENGUE VIRUS VACCINE - The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them. | 2014-04-24 |
20140112954 | METHOD FOR PREPARING HBV VACCINE COMPRISING ALUMINUM ADJUVANT - The present invention discloses a method for preparing HBV Vaccine comprising aluminum adjuvant, which belongs to biological technology field. The method, which is characterized in that aluminum adjuvant Al(OH) | 2014-04-24 |
20140112955 | BIOMARKERS OF IMMUNOTHERAPY EFFICACY - The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy. | 2014-04-24 |
20140112956 | Method for Proliferation of Antigen-Specific T Cells - The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof. | 2014-04-24 |
20140112957 | Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form - The present invention features a long-term controlled release formulation of the nalbuphine pro-soft drug, Sebacoyl dinalbuphine ester, in combination with commonly used pharmaceutical excipient biodegradable polymer PLGA. Said formulation was selected from the following groups of pharmaceutical formulations including such as: tablets, capsules, soft capsules, granules, suspensions, microspheres, oral implants, implantable injections and others. Said long-term controlled release formulation significantly improved the dosage and frequency for administering nalbuphine to once per half month or few months, compared to four to six times per day in the traditional way, which is one of the major features and effects of the present invention. The major improvement of this invention can be achieved by confirmation of the pharmacokinetic profiles and the duration time of efficacy level of drug through in vivo experiments, subsequently improves the dosage and frequency of the traditionally used nalbuphine injections. | 2014-04-24 |
20140112958 | Pancreatic islets of transgenic LEA29Y animals for treating diabetes - The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets. | 2014-04-24 |
20140112959 | TOPICAL STEROID COMPOSITION AND METHOD - Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. | 2014-04-24 |
20140112960 | VISIBLE LIGHT CURABLE HYDROGELS AND METHODS FOR USING - This disclosure provides compositions comprising a visible light-curable mixture capable of forming a biocompatible hydrogel, hydrogels prepared from the hydrogel precursor mixtures, and a biocompatible delivery system comprising a hydrogel. The disclosure also provides a process for preparing a multi layer hydrogel delivery system. | 2014-04-24 |
20140112961 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK, AND NEURONAL INJURIES - A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure. | 2014-04-24 |
20140112962 | PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE INHIBITING THE GROWTH OF CANCER CELLS AND NON-METALLIC SALT LUBRICANT - Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time. | 2014-04-24 |
20140112963 | COMPOSITIONS COMPRISING SOLID PARTICLES ENTRAPPED IN COLLAPSED POLYMERIC MICROSPHERES, AND METHODS OF MAKING THE SAME - A method for modifying or treating solid particles which includes the steps of:
| 2014-04-24 |
20140112964 | COMPOSITIONS COMPRISING HYDROGEL PARTICLES - Provided are stable compositions comprising an aqueous carrier, hydrogel particles comprising one or more polysaccharides, and one or more surfactants. Also provided are methods of making such compositions. | 2014-04-24 |
20140112965 | RUTILE-TYPE TITANIUM DIOXIDE AND COSMETICS USING THE SAME - A Rutile-type titanium dioxide having a rectangular particulate form configured such that major axial planes of rod-shaped particles having a minor axis diameter of 3 to 10 nm are oriented and aggregated in the minor axial direction, and a rod-shaped rutile-type titanium dioxide obtained by treating the rectangular rutile-type titanium dioxide with heat, wherein an apparent average major axial length of the oriented and aggregated particles is 100 to 400 nm, an apparent average minor axial length thereof is 30 to 150 nm, an apparent average axial ratio represented by apparent average major axial length/apparent average minor axial length is 2 to 5 and a specific surface area thereof is 10 to 100 m | 2014-04-24 |
20140112966 | METHOD FOR THICKENING A COSMETIC FORMULATION USING AN ALKALI SWELLABLE EMULSION OF A POLYMER WITH AMPS AND WHICH IS RICH IN ACRYLIC ACID - Process for thickening a composition, through the use of a direct emulsion in water, which is alkali-swellable, of a polymer of the ASE or HASE type, which is both rich in acrylic acid and which has a certain quantity of AMPS. The use of such emulsions simultaneously allows there to be no obligation to use surfactants and organic solvents other than water, and allows the thickening phenomenon to be activated for pHs of less than 7: this latter characteristic is particularly advantageous for formulations intended to be used in contact with skin. | 2014-04-24 |
20140112967 | COSMETIC NEUROTOXIN COMPOSITIONS AND METHODS - Cosmetic compositions include a Clostridial neurotoxin component and a microsphere component. In certain compositions, the composition includes a botulinum toxin and a plurality of swellable microspheres. The compositions are administered to individuals, by injection and the like, to treat a cosmetic defect of deficiency. | 2014-04-24 |
20140112968 | ADHESIVE COMPOSITION FOR CARRYING THERAPEUTIC AGENTS AS DELIVERY VEHICLE ON COATING APPLIED TO VASCULAR GRAFTS - Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed. | 2014-04-24 |
20140112969 | DYNAMIC LOADING OF A THERAPEUTIC FLUID - The invention is directed to a method for therapeutic repair of an injury to bone or tissue comprising providing a structural component, wherein the structural component repairs the injury; and providing a therapeutic fluid, wherein the therapeutic fluid is located within the structural component. | 2014-04-24 |
20140112970 | SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION - The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s). | 2014-04-24 |
20140112971 | Edible Product - The present invention describes an orally administered edible product designed to provide a health benefit in a delivery formulation that will increase ease of use and thus lead to increased compliance and consumption to promote human health and wellness. | 2014-04-24 |
20140112972 | ANTI-ADHESION MEDICAL MATERIAL AND METHOD FOR PRODUCING SAME - Provided is an adhesion preventing medical material including a bioresorbable base material and a polyhydric alcohol or aqueous polyhydric alcohol solution, which contains the polyhydric alcohol, held in the bioresorbable base material. The bioresorbable base material includes a bioresorbable material, and has a swelling degree of 200 to 3,000 mass % and a water elution rate of not higher than 10 mass %. After immersed for 3 hours in water of 25° C. in an amount at least 50 times a total mass of the aqueous polyhydric alcohol solution or aqueous polyhydric alcohol solution and the bioresorbable base material, the polyhydric alcohol remains in an amount of not greater than 30 mass % of that of the polyhydric alcohol before the immersion. | 2014-04-24 |
20140112973 | BIOCOMPATIBLE AND BIODEGRADABLE GRADIENT LAYER SYSTEM FOR REGENERATIVE MEDICINE AND FOR TISSUE SUPPORT - The present invention is directed to a biocompatible and preferably biodegradable gradient layer system comprising at least one set of layers comprising a biocompatible and preferably biodegradable cross-linked polymer and at least one biocompatible and preferably biodegradable support layer, wherein a gradient is preferably formed with respect to the mechanical and/or physical properties of one or more layers of the at least one set of layers comprising a biocompatible and biodegradable cross-linked polymer and/or the at least one biocompatible and preferably biodegradable support layer. The at least one support layer preferably comprises a biocompatible and preferably biodegradable meltable polymer and/or a biocompatible and incorporable material. This biocompatible and preferably biodegradable gradient layer system may be used as a biomaterial for regenerative medicine, particularly as a wound dressing or for tissue support. The present invention also provides means utilizing said inventive gradient layer system and methods for producing same. | 2014-04-24 |
20140112974 | ROPINIROLE-CONTAINING PATCH AND PACKAGE THEREOF - A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein
| 2014-04-24 |
20140112975 | Lipid-Conjugated Rhamnose for Immune System Recruitment and Oncotherapy - L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions. | 2014-04-24 |
20140112976 | Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity - The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems. | 2014-04-24 |
20140112977 | ALLOGENEIC AUTOPHAGOSOME-ENRICHED COMPOSITION FOR THE TREATMENT OF DISEASE - A composition, comprising: an enriched population of autophagosomes derived from a non-small cell lung carcinoma cell line, and wherein the enriched population of autophagosomes includes: one or more toll-like receptor agonists; one or more tumor antigens; and one or more damage-associated molecular pattern molecules. In this way, an off-the-shelf vaccine may be available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types. | 2014-04-24 |
20140112978 | IBUPROFEN-BASED COMPOUND, PREPARATION METHOD, USE, AND FORMULATION OF THE SAME - Disclosed are compounds based on ibuprofen, their preparation methods, uses and pharmaceutical preparation. The compounds have structures shown as formula (1), wherein, m, n are integers and fulfill the requirements of 0≦n≦6, 0≦m≦6, respectively. The preparation methods for the compounds based on ibuprofen are as follows: contacting and reacting 2-(4-isobutyl-phenyl) propionic acid to have contact reaction with a solution of an organic acid ester in the presence of a catalyst under substitution reaction conditions The present compounds can be used to prepare nonsteroidal anti-inflammatory drugs. The preparation can be preparation of fat emulsion, liposome, and dried emulsion and so on. | 2014-04-24 |
20140112979 | METHODS FOR PRODUCING LIPOSOMES - The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulatory/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method. | 2014-04-24 |
20140112981 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2014-04-24 |
20140112982 | CHEWABLE SOFT CAPSULE SHELL AND CHEWABLE SOFT CAPSULE - The present invention relates to a chewable soft capsule shell and a chewable soft capsule, and to a filled jelly sweet and a process for preparing a chewable soft capsule shell or filled jelly sweet, wherein the chewable soft capsule shell comprises gelatin 10%-50%, water retention agent 10%-40%, thickening agent 2%-20%, water 6%-20%, and said soft capsule shell has a thickness of 0.3-1.2 mm. | 2014-04-24 |
20140112983 | NITRITE COMPOSITIONS AND USES THEREOF - The present invention relates to compositions of nitrite and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition of inorganic nitrite, or a pharmaceutically acceptable salt thereof, for supplementation in subjects with diabetes, peripheral artery diseases or in patients with risk factors associated with cardiovascular diseases. | 2014-04-24 |
20140112984 | Crush resistant delayed-release dosage forms - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 2014-04-24 |